The rapid rise of the SARS-CoV-2 variant XFG this summer could make it the dominant strain by the start of the fall COVID season, but experts say current vaccines can likely handle the Omicron-based ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

"Imagine defunding penicillin research in 1943 because of rare reactions. Absurd, right?" Dr. Jerome Adams wrote on X.

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The dollar fell against a basket of currencies, after President Trump said he would nominate Stephen Miran to temporarily join the Federal Reserve's board of governors. "Miran has expressed skepticism ...